EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

51Real-world outcomes of gemcitabine-cisplatin plus durvalumab or pembrolizumab in advanced BTC: K-HBP Cancer Alliance study

Changhoon Yoo, Kyunghye Bang, Moonho Kim, Ju Won Kim, Young-Gyu Park, Chung Ryul Oh, Hyewon Ryu, Ilhwan Kim, Hyehyun Jeong, Hongsik Kim

The Oncologist · 01.06.2026 · 31 (Supplement_1)

DOI: 10.1093/oncolo/oyag205.052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 23.06.2026. Verfasst von Changhoon Yoo und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Following the positive results of TOPAZ-1 and KEYNOTE-966, gemcitabine plus cisplatin (GemCis) combined with durvalumab or pembrolizumab has been established as a global standard first-line regimen for advanced biliary tract cancer (BTC). Because patients treated in routine practice may differ from those enrolled in prospective trials, real-world evaluation of these regimens is warranted.

Method

The K-HBP Cancer Alliance comprises 11 tertiary referral hospitals in Korea. This multicenter retrospective study included patients who received first-line GemCis plus durvalumab or pembrolizumab for unresectable or metastatic BTC. Efficacy endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Results

Between November 2022 and May 2025, 534 patients with BTC (211 [40%] intrahepatic cholangiocarcinoma [iCCA], 212 [40%] extrahepatic cholangiocarcinoma [eCCA], and 111 [20%] gallbladder cancer [GBC]) received GemCis plus durvalumab or pembrolizumab. Median age was 67 years (range, 29-89); 58% were male; 95% had ECOG performance status 0-1; and 81o/o had recurrent or metastatic disease. Median follow-up was 12.0 months (95% Cl, 10.3-13.5). ORR was 20% (95% Cl, 17-24%). Median PFS and OS were 6.6 months (95% Cl, 6.1-7.2) and 14.3 months (95% Cl, 12.9-15.8), respectively. One-year PFS and OS rates were 26% and 58%, respectively. Primary tumor site was not associated with PFS or OS. Elevated CA 19-9 (> median) was associated with inferior PFS (HR, 1.35; 95% Cl, 1.08-1.70; p = 0.009) and OS (HR, 1.53; 95% Cl, 1.13-2.03; p = 0.006).

Conclusion

In this large multicenter real-world cohort, GemCis plus durvalumab or pembrolizumab demonstrated efficacy outcomes consistent with prospective trials.

Zitieren

APA

Yoo, C., Bang, K., Kim, M., Kim, J. W., Park, Y., Oh, C. R., Ryu, H., Kim, I., Jeong, H., & Kim, H. (2026). 51Real-world outcomes of gemcitabine-cisplatin plus durvalumab or pembrolizumab in advanced BTC: K-HBP Cancer Alliance study. The Oncologist, 31(Supplement_1). https://doi.org/10.1093/oncolo/oyag205.052

Vancouver

Yoo C, Bang K, Kim M, Kim JW, Park Y, Oh CR, et al. 51Real-world outcomes of gemcitabine-cisplatin plus durvalumab or pembrolizumab in advanced BTC: K-HBP Cancer Alliance study. The Oncologist. 2026;31(Supplement_1). doi:10.1093/oncolo/oyag205.052

BibTeX
@article{Yoo2026,
  author = {Yoo, Changhoon and Bang, Kyunghye and Kim, Moonho and Kim, Ju Won and Park, Young-Gyu and Oh, Chung Ryul and Ryu, Hyewon and Kim, Ilhwan and Jeong, Hyehyun and Kim, Hongsik},
  title = {51Real-world outcomes of gemcitabine-cisplatin plus durvalumab or pembrolizumab in advanced BTC: K-HBP Cancer Alliance study},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {Supplement_1},
  doi = {10.1093/oncolo/oyag205.052}
}
Kostenlos starten →